Topics:
Genitourinary Cancers • Medical Oncology • NCI-CCC Tumor Board Question • Urologic Oncology • Duke • NCI-CCC GU Tumor Board Question • Duke GU Tumor Board
When will you recommend enfortumab vedotin plus pembrolizumab as first-line treatment of metastatic urothelial carcinoma for cisplatin-ineligible patients?
Will you use it rather than a carboplatin-containing regimen?
Answer from: Medical Oncologist at Academic Institution
This is a timely question given the US FDA approval of the pembro/EV combination on 4/3/2023. Currently, the label is for patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy. There are a variety of definitions for cisplatin ineli...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
The enfortumab vedotin (EV) + pembrolizumab regimen received accelerated approval by the US FDA in April 2023 for cisplatin-ineligible patients with advanced urothelial carcinoma. The approval was based on cohorts A (Phase I/Ib) and K (randomized phase II comparison of EV vs. EV+pembrolizumab) of th...